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Abstract
Small intestine neuroendocrine tumors (SI-NETs) represent the most common histotype among small intestine neoplasms, and
metastatic disease is usually present at diagnosis. A retrospective series of 52 sporadic primary surgically resected SI-NETs,
which were metastatic at diagnosis, was analyzed by high-coverage target sequencing (HCTS) for the mutational status of 57
genes and copy number status of 40 genes selected from recently published genome sequencing data. Seven genes were found to
be recurrently mutated:CDKN1B (9.6%), APC andCDKN2C (each 7.7%), BRAF,KRAS, PIK3CA, and TP53 (each 3.8%). Copy
number analysis showed frequent allelic loss of 4 genes located on chromosome 18 (BCL2,CDH19,DCC, and SMAD4) in 23/52
(44.2%) and losses on chromosomes 11 (38%) and 16 (15%). Other recurrent copy number variations were gains for genes
located on chromosomes 4 (31%), 5 (27%), 14 (36%), and 20 (20%). Univariate survival analysis showed that SRC gene copy
number gains were associated with a poorer prognosis (p = 0.047). Recurrent copy number variations are important events in SI-
NET and SRC may represent a novel prognostic biomarker for this tumor type.
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Introduction
Small intestinal neuroendocrine tumor (SI-NET) is the most
frequent cancer type of the small bowel [21]. Despite slow-
growing [18, 19], SI-NET is a deadly disease usually diag-
nosed at metastatic stage [12]. Many patients are asymptom-
atic, and the disease is often diagnosed incidentally. Less fre-
quently SI-NETs are responsible for a carcinoid syndrome,
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which usually occurs in patients with liver metastases, due to
excessive production and release of hormones and substances
such as serotonin and prostaglandins [5].
The genetics of SI-NET remains elusive. Genome sequenc-
ing of the two independent series so far published provided
dissonant information regarding recurrent somatic gene muta-
tions, suggesting multigene potential mechanisms of carcino-
genesis [2, 10]. In particular, a combination of whole-genome
and exome sequencing performed on 50 SI-NETs showed
somatic mutations of the CDKN1B gene in 14% of cases
[10], which were not found in the exome sequencing study
of 48 SI-NET [2]. This latter study identified mutations in
several other cancer genes, although none was recurrently
altered [2]. A single study reported a relatively high frequency
of APC gene alterations (7 of 30 cases; 23%) [4], but only one
mutation was found in one [10] of the two genome sequencing
studies [2, 10].
At variance with gene mutations, chromosomal and gene
copy number alterations characterize a significant portion of
SI-NETs [2, 10, 13]. Consistent chromosomal and gene copy
number alterations reported by the same two genome sequenc-
ing studies included loss of chromosome 18 in about 50% and
of chromosome 16 in up to 18% of cases, whereas gains were
in chromosomes 4, 5, 7, 14, and 20 occurring in a range from
10 to 30% of cases [2, 10]. Allelic loss of chromosome 18 is
the most frequent anomaly that has been consistently reported
in several different studies [1, 7, 11, 14, 15, 24], whereas gains
of chromosome 14 [1] and 20pter-p11.21 [11] have been as-
sociated with shorter patients’ survival.
In this paper, we studied a well-characterized cohort of 52
primary SI-NETs that were metastatic at diagnosis
performing: (i) a targeted deep sequencingmutational analysis
for 57 relevant genes; (ii) copy number variation (CNV) anal-
ysis of a selected number of 40 genes located in the most
frequently altered chromosomes; (iii) survival analysis to in-
vestigate the potential clinical relevance of the results.
Materials and methods
Patients and samples A retrospective series (1997–2012) of
52 sporadic surgically resected primary intestinal neuroendo-
crine tumors (47 ileal, 4 duodenal, and 1 jejunal) were re-
trieved from the formalin-fixed paraffin-embedded (FFPE)
archives of the ARC-Net Biobank at Verona University
Hospital and from the University of Genoa/IRCCS S.
Martino-IST University Hospital. All cases were reclassified
according toWHO 2010 [3] and staging was assessed accord-
ing to AJCC/UICC 7th edition [9]. Matched normal small
intestine samples were used to determine the somatic/
germline nature of mutations.
In 25 cases, sufficient material was available for the con-
struction of 1-mm core tissue microarrays (TMAs) using the
Galileo CK3500 Arrayer (www.isenet.it), a semiautomatic
and computer-assisted TMA platform. Three tissue cores per
case were analyzed.
Clinico-pathological characteristics of the sample cohort
along with the molecular analyses conducted in this study
are reported in Table 1 and Supplementary Table 1.
DNA extraction and qualification DNA was obtained from
matched tumor and normal FFPE tissues, after enrichment
for neoplastic cellularity to at least 70% using manual micro-
dissection of 10 consecutive 4-μm sections. DNAwas purified
using the QIAamp DNA FFPE Tissue Kit (Qiagen) and qual-
ified as reported [25, 27]. Briefly, DNAwas quantified using
Qubit DNA HS Assay kit (ThermoFisher) and purity was
evaluated using NanoDrop ND-2000 [25]; integrity was in-
vestigated using the BIOMED protocol, and only DNA sam-
ples producing fragments of at least 200 bp were deemed
usable for NGS [27].
RNA extraction and qualification RNAwas obtained from 10
consecutive 6-μm FFPE sections using RecoverAll total
nucleic acid isolation kit protocol (ThermoFisher). RNAwas
quantified using Qubit RNA BR Assay Kit (ThermoFisher)
and qualified using Agilent RNA 6000 Nano Kit (Agilent
Technologies). A RNA Integrity Number (RIN) over 5 was
considered suitable.
Table 1 Clinical-pathological features of the 52 SI-NETs considered in
the study
Clinico-pathological features Total (52) [%]
Sex 30M 22F
Age 46.1 ± 24.0
Dimension (cm) 2.2 ± 1.3
Differentiation WD 49 [94.2]
PD 3 [5.8]
Grade G1 36 [69.2]
G2 13 [25.0]
G3 3 [5.8]
Stage UICC/ENETS IIIB 22 [42.3]
IV 30 [57.7]
R R1 4 [7.7]
R0 48 [92.3]
Vascular invasion Present 35 [67.3]
Absent 17 [32.7]
Perineural invasion Present 32 [61.5]
Absent 20 [38.5]
Necrosis Present 3 [5.8]
Absent 49 [94.2]
WD well differentiated, PD poorly differentiated, R1 positive resection
margins, R0 negative resection margins
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High-coverage target sequencing Matched tumor/normal
DNA from all FFPE samples was subjected to targeted
next-generation sequencing (NGS). Three multigene
panels were used: the 50-gene Ion AmpliSeq Cancer
Hotspot panel v2 (ThermoFisher) and two AmpliSeq
custom panels.
The first panel explores mutation status of selected hot-spot
regions of 50 cancer-related genes: ABL1, AKT1, ALK, APC,
ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR,
ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3,
FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2,
JAK2, JAK3, KDR/VEGFR2, KIT, KRAS,MET,MLH1,MPL,
NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN,
PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC,
STK11, TP53, and VHL. Details on target regions of the com-
mercial panel are at http://www.thermofisher.com.
The second panel has been designed for the mutational
analysis of 7 genes selected upon the results of published
whole genome, exome, and targeted sequencing of SI-NETs
series [2, 4, 10, 13]: ATRX, CDKN1B, CDKN2C, DAXX,
H3F3A, MEN1, and TERT.
The third panel investigates copy number variation (CNV)
status of 40 genes reported as altered in SI-NETs [2, 7, 10, 11,
13, 15]: AKT1, APC, AURKA, BCL2, BCL2L2, BRAF,CDH1,
CDH19, CDKN1B, CDKN2A, DCC, EGFR, ERBB2,
FBXW7, FGFR3, FHIT, FOS, GNAS, HRAS, KDR, KIT,
MAP2K2, MDM2, MEN1, MET, MYC, MYCL1, PDGFRA,
PIK3CA, PIK3CD, PTEN, RICTOR, SDHA, SDHB, SDHD,
SMAD4, SMAD5, SOX12, SRC, and TP53. Details on target
regions of the CNV custom panel are in Supplementary
Table 2A.
Twenty nanograms of DNAwere used for each multiplex
PCR amplification. The quality of the obtained libraries was
evaluated by the Agilent 2100 Bioanalyzer on-chip electro-
phoresis (Agilent Technologies). Emulsion PCR to construct
the libraries of clonal sequences was performed with the Ion
OneTouch™ OT2 System (ThermoFisher). Sequencing was
run on the Ion Proton (PI, ThermoFisher) loaded with Ion PI
Chip v2.
Sequencing data analysis Base calling, alignment to the hg19
human reference genome, and variant calling were done using
the Torrent Suite Software v.5.0 (ThermoFisher). Called var-
iants were annotated using a custom pipeline based on vcflib
(https://github.com/ekg/vcflib), SnpSift [6], the Variant Effect
Predictor (VEP) software [17], and NCBI RefSeq database.
Filtering of variants was performed by: (i) removal of
germline variants and (ii) visual verification of alignments
on the IGV software v2.3 [26]. This latter step is key to re-
move false calls due to technique-dependent mispriming or
sample age-related deamination, which cannot be ruled out
by automated variant calling and filtering procedures
(Supplementary Table 2B).
CNV analysis using next-generation sequencing For all sam-
ples, a CNV baseline for AmpliSeq custom panels was per-
formed using 10 genomic male DNA extracted from normal
tissues included in FFPE samples. CNV was evaluated com-
paring BAM files of sequenced libraries to baseline through a
custom workflow pipeline created on IonReporter 5.0 soft-
ware. Copy number variation calling of genes included in
the Ion AmpliSeq Cancer Hotspot panel v2 and custom panel
was performed using followed criteria: (i) a median of the
absolute values of all pairwise differences (MAPD) score un-
der 1; (ii) a CNV confidence number major than 20; (iii) a tiles
number major than 10. An orthogonal cross-validation using
FISH or qPCR was performed. A chromosome integrity num-
ber score was evaluated for each sample dividing length of
altered chromosomes to length of chromosome regions
investigated.
CNV validation by quantitative-PCR Q-PCR analysis of copy
numbers was applied to all 52 SI-NETs for selected loci. All
target and reference assays were purchased from
ThermoFisher Scientific. RNaseP was used as endogenous
control for normalization of analyzed loci. The following as-
says were used: AKT1 (Hs02893205), BCL2 (Hs01500302),
CDH19 (Hs02826809), DCC (Hs02317964), FHIT
(H s 03491211 ) , MET (H s 04951661 ) , P IK3CD
(Hs04540050 ) , SMAD4 (Hs06483146 ) , SOX12
(Hs02822764), SRC (Hs07169853), SDHB (Hs00124581),
and RNaseP (part number 4403326). The experimental proce-
dure recommended by the manufacturer (Applied
Biosystems) was followed. Twenty nanogram genomic
DNAwas used in the q-PCR reaction, and a negative control
was analyzed in parallel. All q-PCR reactions were run in
quadruplicate in a 7900HT qRT-PCR machine (Applied
Biosystems) using standard cycling conditions of 10 min at
95 °C, followed by 40 cycles of [95 °C for 15 s and at 60 °C
for 1 min]. Pooled normal FFPE DNAwas used as calibrator
and as reference unbiased genome. Microsatellite markers
D18S484, D18S51, and D18S1110 were used to confirm
LOH/homozygous deletion, respectively, in DCC, BCL2,
and SMAD4 locus.
Fluorescent in situ hybridization analysis FISH analysis was
performed to evaluate CNV status of chromosome 18q, 14q,
and SRC gene. The LSI IGH/BCL2 dual color, dual fusion
translocation probe (Vysis Inc./Abbott) was used for chromo-
some 18q. The TelVysion 14q probe (Vysis Inc./Abbott) was
used to evaluate chromosome 14q status as reported in a pre-
vious work [1]. A custom FISH probe was developed to eval-
uate the status of SRC gene (chr20q11.23). The custom FISH
probe labeled SRC (chr20q11.23) in Spectrum Red and the
control locus 20p11.21 in Spectrum Green (Empire
Genomics). FISH analysis was performed according to the
manufacturer’s protocols.
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Expression analysis for SRC gene An ampliseq RNA custom
panel was built to analyze the expression levels of SRC and
included a series of genes to normalize them (ACTB, CDH17,
GC, HPRT1, KCNJ3, KIF12, MIA2, MUC13, RNF213,
RPRM, SOX21). In brief, 1 μg of RNAwas retro-transcribed
and submitted for library construction. The quality of the ob-
tained libraries was evaluated by the Agilent 2100
Bioanalyzer on-chip electrophoresis (Agilent Technologies).
Emulsion PCR to construct the libraries of clonal sequences
was performed with the Ion OneTouch™ OT2 System (Life
Technologies). Sequencing was performed on Ion PGM load-
ing 318v2 chip, reads were aligned to reference genome (hg19
Homo sapiens RNA Canonical Transcript). Normalization
was performed dividing the number of reads obtained for
SRC transcript by the sum of reads obtained for the other
genes and expressed as reads per thousands of reads.
Immunohistochemistry Immunohistostaining was performed
with Leica Microsystems Bond-Max Autostainer System
using the antibodies listed in Supplementary Table 3 on
3-μm FFPE sections from tissue blocks containing represen-
tative core samples. Immunolabeling for all antibodies was
performed according to manufacturer protocols; normal intes-
tinal tissue was used as positive control. Sections incubated
without the primary antibodies served as negative control.
Statistical analysis One-way ANOVA, Kruskal-Wallis test,
Fisher’s test with Monte Carlo simulation, and Fisher’s exact
test were used as appropriate; correction for multiple compar-
isons was performed according to Benjamini-Hochberg. For
comparison of Kaplan-Meier survival curves, Mantel-Cox test
was used; for multivariable survival analysis, stepwise Cox
proportional hazards regression was used; selection of the best
model was performed using the Benter^ algorithm. For all the
analyses, a p value below 0.05 was considered as significant.
All analyses were performed using Medcalc for Windows
version 15.6 (MedCalc Software, Ostend, Belgium) and R v.
3.2.1; multivariable Cox regression was done with R using
survival library v.2.38-2.
Results
Clinico-pathological characteristics of the series Clinico-path-
ological data are detailed in Table 1 and Supplementary
Table 1. Tumor grade was G1 in 36 (69.2%), G2 in 13
(25.0%), and G3 in 3 cases (5.8%). Vascular and perineural
invasions were present in 35 (67.3%) and 32 (61.5%) cases,
respectively. The ENETS and UICC pathologic stages over-
lapped and were: stage IIIB in 22 and IV in 30.
Mutational profiles of small intestinal neuroendocrine tumors
DNA from all samples was successfully amplified in
multiplex PCR for the 57 selected genes and adequate libraries
for deep sequencing were obtained. The mean read length was
103 base pairs and a mean coverage of 5893× was achieved,
with 97.2% target bases covered more than 100×. Aminimum
coverage of 20× was obtained in all cases. A mean of 0.6
mutation was detected in all series for the 57 genes analyzed.
In the whole cohort, 18 (34.6%) samples showed somatic
mutations: 12 (23.1%) affected by one mutation; 6 (11.5%)
affected by more than one. The remaining 34 (65.4%) tumors
resulted wild type for the 57 genes assayed (Fig. 1a, Table 2).
The most frequently mutated genes wereCDKN1B (9.6%),
followed by APC and CDKN2C (each 7.7%), BRAF, KRAS,
PIK3CA, and TP53 (each 3.8%). The details of the somatic
mutations detected are reported in Supplementary Table 4.
Five mutations in tumor suppressor genes (FGFR3, TP53,
CDKN2C, APC, RB1) had a high allelic frequency (> 60%)
compatible with homozygous alteration in a large fraction of
tumor cells. Fourteen mutations, prevalently in oncogenes or
haplo-insufficient tumor suppressor genes, had a frequency
between 25 and 57%, compatible with heterozygous alteration
in all tumor cells or with homozygous alteration in a consistent
(30–50% of total tumor) subpopulation of neoplastic cells.
Finally, 11 mutations had a frequency equal to or below
20%, compatible with heterozygous or homozygous alteration
of smaller subclones. Notably, the same tumor (e.g., case G5)
often bore different mutations with both high and low frequen-
cies, suggesting molecular heterogeneity.
Copy number variations in selected genes Copy number var-
iations were evaluated using NGS and validated by q-PCR
and FISH. The results are summarized in Table 3, detailed in
Supplementary Table 5 and illustrated Fig. 1b and
Supplementary Fig. 1.
A mean of 6.5 CNV was found in the series for the 40
genes investigated. Forty-eight (92.3%) samples showed so-
matic CNV: 1 (1.9%) affected by one CNV and 47 (90.4%)
affected by more than one CNV. Four (7.7%) samples showed
no CNV event. The most frequent event was loss of a single
copy (LOH) of theCDH19 gene located on 18q22 locus in 24/
52 (46.2%). Other genes analyzed and located on chromo-
some 18q (BCL2, DCC, SMAD4) were mostly affected by
LOH. In particular, 23 samples (44.2%) showed copy loss of
one or more genes located on this chromosomal region. LOH
Fig. 1 Genetic landscape of 52 SI-NET. a The upper histogram shows the
number of mutations (blue) and CNV (green) in recurrently altered genes
for each sample. The central matrix shows 16 of 57 genes that were
mutated in the whole cohort; alterations are annotated by different colors
according to their impact on the gene product as illustrated in the panel on
the right. b Summary of somatic copy number variations determined for
52 human SI-NETs. Significant gains (red) and losses (cyan) were deter-
mined for the chromosomal regions and are plotted according to their
frequencies on the right
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of DCC, BCL2, and SMAD4 were validated using microsatel-
lite marker quantification between tumor and matched normal
samples for each specific locus. IHC analysis for CDH1,
SMAD4, and CDKN1B was possible for the 25 cases includ-
ed in the TMAs; in all samples affected by the loss of one gene
copy, a significant decrease in the corresponding protein ex-
pression was observed (Supplementary Fig. 2). Frequent copy
gains were detected in FOS gene (19/52, 36.5%) followed by
AKT1 (16/52; 30.8%) and KIT,KDR, and PDGFRA locus (15/
52, 28.8%).
Identification of molecular subgroups To identify potential
molecular subgroups in SI-NET, we separated samples
according to their prevalent molecular features. This ap-
proach identified three distinct groups as illustrated in
Fig. 1. Group 1 included 18 samples characterized by
presence of somatic mutations. Groups 2 and 3 together
included 34 samples, each with chromosome copy num-
ber alterations and no somatic mutations. In particular,
group 2 comprised samples featured by LOH in at least
2 genes located on chromosome 18, while group 3 com-
prised samples with no mutations and low or no LOH
affecting chromosome 18 genes.
Survival analysis Follow-up data was available for 47 cases.
Median survival was 71.0 (range 4–160) months and 16
(34.0%) subjects died of disease. To identify clinico-
pathological markers of poor prognosis, we considered at uni-
variate analysis: sex, age at diagnosis (under/over 50 years),
and presence of nodal or distant metastases (stage IIIB vs. IV).
The analysis showed no significant differences about
prognosis performance among these markers. Whenmatching
clinical data and molecular features, copy gain of SRC was
identified as the only molecular marker associated to poor
prognosis (Fig. 2). Of interest, cases with SRC copy gain
showed less perineural invasion (p = 0.019); no other correla-
tion with clinicopathological features was found. Of note, a
Table 3 Copy number variations for selected genes in 52 SI-NETs.
Genes are listed per alphabetical order
Gene Chromosomal location Gain or loss Total (52) [%]
AKT1 14 Gain 16 [30.8]
APC 5 LOH 2 [3.8]
AURKA 20 Gain 6 [11.5]
BCL2 18 LOH 22 [42.3]
BCL2L2 14 Gain 11 [21.2]
BRAF 7 Gain 9 [17.3]
CDH1 16 LOH 8 [15.4]
CDH19 18 LOH 24 [46.2]
CDKN1B 12 LOH 7 [13.5]
CDKN2A 9 LOH 3 [5.8]
DCC 18 LOH 22 [42.3]
EGFR 7 Gain 4 [7.7]
ERBB2 17 Gain 0 [0]
FBXW7 4 LOH 1 [1.9]
FGFR3 4 Gain 3 [5.8]
FHIT 3 LOH 3 [5.8]
FOS 14 Gain 19 [36.5]
GNAS 20 Gain 5 [9.6]
HRAS 11 LOH 9 [17.3]
KDR 4 Gain 15 [28.8]
KIT 4 Gain 15 [28.8]
MAP2K2 19 Gain 11 [21.2]
MDM2 12 Gain 3 [5.8]
MEN1 11 LOH 7 [13.5]
MET 7 Gain 9 [17.3]
MYC 8 Gain 2 [3.8]
MYCL1 1 Gain 6 [11.5]
PDGFRA 4 Gain 15 [28.8]
PIK3CA 3 Gain 0 [0]
PIK3CD 1 LOH 0 [0]
PTEN 10 LOH 2 [3.8]
RICTOR 5 Gain 2 [3.8]
SDHA 5 Gain 15 [28.8]
SDHB 1 LOH 0 [0]
SDHD 16 LOH 18 [34.6]
SMAD4 18 LOH 15 [28.8]
SMAD5 5 Gain 11 [21.2]
SOX12 20 Gain 7 [13.5]
SRC 20 Gain 13 [25.0]
TP53 17 LOH 0 [0]
Table 2 Mutated genes in the 52 SI-NETs
GENE Total (52) [%] M N S D F
APC 4 [7.7] 1 3 – – –
ATRX 1 [1.9] – – 1 – –
BRAF 2 [3.8] 2 – – – –
CDKN1B 5 [9.6] 2 1 – – 2
CDKN2C/INK4C 4 [7.7] 3 – 1 – –
CTNNB1 1 [1.9] 1 – – – –
FBXW7 1 [1.9] 1 – – – –
FGFR3 1 [1.9] 1 – – – –
GNAS 1 [1.9] 1 – – – –
KRAS 2 [3.8] 2 – – – –
PIK3CA 2 [3.8] 1 1 – – –
RB1 1 [1.9] – – 1 – –
SRC 1 [1.9] – 1 – – –
TERT 1 [1.9] 1 – – – –
TP53 2 [3.8] 2 – – – –
M missense mutation, N nonsense mutation, S splice site alteration, D
deletion, F frameshift mutation
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strong correlation between age at diagnosis over 50 years and
copy gain at the FOS gene locus was observed (p = 0.001).
Molecular subgroups as previously defined by Karpathakis
et al. [13] did not associate with any difference in survival
(p = 0.73).
SRC expression analysisTo verify the impact of SRC copy gain
on transcript levels, we performed targeted RNA sequencing
on the 14 cases with available residual tissue for research
purposes. These included 4 cases with SRC copy gains and
10 without locus alteration according to CNV analysis. The
number of reads obtained for SRC was normalized to the sum
of the reads obtained for a set of 11 control genes and
expressed as normalized counts (reads per thousands of con-
trol reads). Cases were grouped according to their genomic
SRC status (gain vs. wild-type) and Mann-Whitney test was
performed to compare them (Supplementary Fig. 3).
Normalized counts of SRC transcript were almost 3 times
higher in the BGain^ group (median 38.4, 1st–3rd quartiles
31.0–82.2) than in the BWild-type^ group (median 12.6, 1st–
3rd quartiles 3.4–19.0, p = 0.0020).
Discussion
The SI-NETs molecular landscape and its clinical implications
are still to be fully elucidated.
In this paper, we focused on the major genetic SI-
NET alterations in a cohort of 52 sporadic surgically
resected advanced SI-NETs. Our study: (i) demonstrated
that mutations in gene coding sequences are a relatively
rare event; (ii) CNV is relatively frequent, affecting
LOH of chromosome 18q in more than 40% of the
samples; (iii) SRC gene gains are associated to a poorer
patients’ survival.
Only 18 (34.6%) samples were characterized by somatic
mutations in the 57 analyzed genes in the NGS mutational
analysis. Our findings were concordant with those observed
by Francis et al. [10] regarding mutation frequencies for
CDKN1B (9.6%) and BRAF (3.8%) genes. Moreover, we
found a significant mutational rate for APC (7.7%),
confirming previous reports obtained by conventional se-
quencing methods [4, 23].
Unreported findings [4, 10, 22] were the mutations ob-
served in PIK3CA (3.8%), TP53 (3.8%), KRAS (3.8%), and
CDKN2C (7.7%) genes. Cases affected by these mutations did
not show any peculiar clinico-pathological feature.
Unlike the poor mutational landscape observed in our
series, copy number analysis in selected genes showed
recurrent and frequent alterations in the whole cohort.
As previously reported in several studies [1, 8, 11, 15,
20], in our series, we also observed copy loss of genes
located on chromosome 18 (DCC, SMAD4, BCL2, and
CDH19; 24/52, 46.2%). Again in line with previous
studies [1, 2, 10, 11, 14–16], we identified copy number
gains in genes located in chromosomes 4 (FGFR3, KDR, KIT,
and PDGFRA), 5 (RICTOR, SDHA and SMAD5), 7 (EGFR
and BRAF), 14 (AKT1, BCL2L2, and FOS), and 20 (AURKA,
GNAS, SOX12, and SRC).
Among the principal genes affected by copy number
variations, no mutually exclusive gene was observed
between those located on chromosomes 14 and 18.
This was at variance from what previously described
by Hashemi et al. [11] but similar to what reported by
Anderson et al. [1].
Abundance of genes affected by CNV suggests that
aberrations in the genomic/chromosomal structure may
play an important role in SI-NET biology. Also, surviv-
al analysis supported this hypothesis. Correlating clini-
cal data and molecular features, we identified no corre-
lation between prognosis and gene mutation, but did
observe a significant relationship by univariate analysis
between copy gain of SRC gene and poor patient prog-
nosis (p = 0.047). Copy gains of the SRC gene in SI-
NET were first identified by Banck et al. in a series of
48 cases, suggesting SRC as potential therapeutic target
for this disease [2]. We also report that copy gain of the
SRC gene is associated with elevated mRNA levels.
This was also true for case #V22, presenting 5 copies
of SRC and an apparently contradictive nonsense muta-
tion. In this case, the relative abundance of the SRC
transcript was one of the highest (45.8 normalized
counts vs. a median of 12.6 normalized counts for
SRC wild-type cases). Therefore, the nonsense mutation
was likely a passenger event with no evident impact on
SRC expression.
Fig. 2 Overall survival according to molecular and pathological features.
Overall survival of SI-NETs (n = 47) is significantly affected by gain
occurring in SRC locus gene (p = 0.047). Vertical axis indicates percent
survival; horizontal axis shows time expressed in months. Kaplan–Meier
and log-rank statistics were used to determine levels of significance
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A recent integrative molecular analysis on 47 SI-NET by
Karpathakis et al. [13] highlighted the presence of 3 molecular
subgroups via matched copy number and methylation profile
results. The most relevant included 26 samples (55% of whole
cohort) characterized by loss of chromosome 18 with concur-
rent CDKN1B mutation and better survival compared to the
other two molecular subgroups. In our study, no concurrence
of chromosome 18 loss (44.2%) and CDKN1B mutation
(9.6%) was observed. Moreover, classifying our cohort into
the three groups of Karpathakis et al., we did not observe any
statistically significant correlation with prognosis.
In our study, at variance with the current literature [1, 11],
poor prognosis was not associated with gains of genes at 20p
or 14q loci. To test CNV status of these loci, we analyzed
SOX12 (locus 20p13), FOS (locus 14q24.3), and AKT1 (locus
14q32.33) genes as surrogate for such chromosome arms.
Interestingly, FOS copy gain was strongly associated with
another marker of poor prognosis in our study: advanced age
at diagnosis (Fisher’s exact test p = 0.001). This might explain
why Anderson et al. identified gain of 14q as a poor prognos-
tic marker. In fact, in that study, all samples characterized by
this alteration had an advanced age at diagnosis (i.e., over
50 years old) [1].
In conclusion, our study provides additional data to define
the genetic landscape of sporadic SI-NETs, highlighting copy
number variations as a central molecular event in this tumor
type, not only for understanding SI-NET biology, but also
with prognostic significance.
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